NCT04620291View on ClinicalTrials.gov

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

HIV-1-infection

Interventions

BIOLOGICAL

UB-421 SC

The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.